Biogen（BIIB）株式概要
バイオジェン社は、米国、欧州、ドイツ、アジア、および国際的に治療薬の発見、開発、製造、販売を行っています。 詳細
BIIB Community Fair Values
Create NarrativeSee what 107 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Pharmaceuticals & Biotech opportunity
Biogen Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$190.68 |
| 52週高値 | US$202.41 |
| 52週安値 | US$115.25 |
| ベータ | 0.19 |
| 1ヶ月の変化 | 10.64% |
| 3ヶ月変化 | 2.87% |
| 1年変化 | 62.68% |
| 3年間の変化 | -39.13% |
| 5年間の変化 | -30.41% |
| IPOからの変化 | 6,084.22% |
最新ニュース
ナラティブ更新 • May 04
BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential
Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.
ナラティブ更新 • Apr 20
BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism
Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.Seeking Alpha • Apr 06
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease
Summary Eisai (ESALF) and Biogen (BIIB) have presented inconsistent efficacy claims for Leqembi in Alzheimer's, particularly regarding APOE4 genetic subgroups. Real-world data may reveal Leqembi is only marginally effective for APOE4 single-copy carriers, with little benefit for non-carriers or double-copy carriers. BIIB may be more resilient than ESALF to negative Leqembi developments due to pipeline diversity, but no near-term catalysts are evident for BIIB stock movement. Efforts to expand Leqembi’s market may be misguided; regulatory scrutiny and emerging alternatives could further limit its commercial potential. Read the full article on Seeking AlphaRecent updates
ナラティブ更新 • May 04
BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential
Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.ナラティブ更新 • Apr 20
BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism
Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.Seeking Alpha • Apr 06
Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease
Summary Eisai (ESALF) and Biogen (BIIB) have presented inconsistent efficacy claims for Leqembi in Alzheimer's, particularly regarding APOE4 genetic subgroups. Real-world data may reveal Leqembi is only marginally effective for APOE4 single-copy carriers, with little benefit for non-carriers or double-copy carriers. BIIB may be more resilient than ESALF to negative Leqembi developments due to pipeline diversity, but no near-term catalysts are evident for BIIB stock movement. Efforts to expand Leqembi’s market may be misguided; regulatory scrutiny and emerging alternatives could further limit its commercial potential. Read the full article on Seeking Alphaナラティブ更新 • Apr 05
BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism
The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.
新しいナラティブ • Mar 31
Biogen Inc. (BIIB): The "Post-MS" Pivot and the Alzheimer’s Momentum
Biogen Inc. (BIIB) is navigating a high-stakes transition year in 2026, closing the March 31, 2026, session at $178.98 USD on the NASDAQ.ナラティブ更新 • Mar 22
BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism
Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.
ナラティブ更新 • Mar 07
BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside
The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.ナラティブ更新 • Feb 21
BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk
The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.分析記事 • Feb 13
There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings
Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...ナラティブ更新 • Feb 07
BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential
Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.ナラティブ更新 • Jan 23
BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations
Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.ナラティブ更新 • Jan 09
BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook
Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.ナラティブ更新 • Dec 24
BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance
Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.ナラティブ更新 • Dec 10
BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead
Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.ナラティブ更新 • Nov 26
BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead
Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.ナラティブ更新 • Nov 12
BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025
Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.ナラティブ更新 • Oct 29
Easing Policy Risks And New Therapy Launches Will Drive Shares Higher
Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.ナラティブ更新 • Oct 15
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.ナラティブ更新 • Sep 20
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.ナラティブ更新 • Sep 05
Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth
Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.分析記事 • Jun 17
Biogen (NASDAQ:BIIB) Seems To Use Debt Quite Sensibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Apr 25
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?
Summary Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis treatments face patent expirations and competition, pressuring revenue; new Alzheimer's Disease and rare disease treatments could drive future growth. Financially, Biogen remains profitable with strong FCF, but reduced R&D spending and lack of insider buying or share buybacks are concerning. I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data. Read the full article on Seeking AlphaSeeking Alpha • Mar 27
Biogen: Balancing Risks And Opportunities
Summary Biogen's new management is diversifying its product portfolio and optimizing costs, but faces significant risks from market share loss and generic competition. The fair valuation of Biogen shares is $149, close to the current price, leading to a "Hold" rating and a recommended purchase price of $115-120. Key growth drivers include potential success with Leqembi, Skyclarys, and optimization efforts, while risks involve slow sales of new products and competition. Despite a 35% stock price drop in 2024, Biogen's strategic steps and increased margins suggest shares are near fair value. Read the full article on Seeking AlphaSeeking Alpha • Feb 15
Biogen Q4 Earnings Review: Why I'm Calling Time On This 'Powder Puff' Pharma
Summary Biogen's Q4 2024 earnings showed slight revenue growth but Wall Street remains unimpressed due to weak guidance and declining key drug franchises. Leqembi's commercial performance is disappointing, mirroring Aduhelm's failure, and Biogen's pipeline lacks promising products to drive future growth. The multiple sclerosis franchise is in decline, and new drug approvals like Qalsody and Skyclarys have shown minimal revenue impact. Biogen's strategic missteps, including the failed Sage Therapeutics acquisition, underscore a lack of innovation and direction, leading to a "sell" rating. Read the full article on Seeking Alpha株主還元
| BIIB | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | -1.9% | 3.7% | 3.2% |
| 1Y | 62.7% | 41.9% | 31.0% |
業界別リターン: BIIB過去 1 年間で41.9 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: BIIB過去 1 年間で31 % の収益を上げたUS市場を上回りました。
価格変動
| BIIB volatility | |
|---|---|
| BIIB Average Weekly Movement | 4.6% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: BIIB 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。
時間の経過による変動: BIIBの 週次ボラティリティ ( 5% ) は過去 1 年間安定しています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1978 | 7,500 | Chris Viehbacher | www.biogen.com |
バイオジェン社は、米国、欧州、ドイツ、アジア、および国際的に治療薬の発見、開発、製造、販売を行っている。同社は、多発性硬化症（MS）治療薬としてTECFIDERA、VUMERITY、AVONEX、PLEGRIDY、TYSABRI、脊髄性筋萎縮症治療薬としてSPINRAZA、フリードライヒ失調症治療薬としてSKYCLARYS、筋萎縮性側索硬化症治療薬としてQALSODYを提供している；斑状乾癬治療薬FUMADERM、ENBRELに類似したエタネルセプトバイオシミラーBENEPALI、HUMIRAに類似したアダリムマブバイオシミラーIMRALDI、REMICADEに類似したインフリキシマブバイオシミラーFLIXABI。アルツハイマー病治療薬LEQEMBI、産後うつ病治療薬ZURZUVAE、非ホジキンリンパ腫、慢性リンパ性白血病（CLL）、関節リウマチ、2種類のANCA関連血管炎、尋常性天疱瘡治療薬RITUXANを提供している；非ホジキンリンパ腫およびCLLに対するリツキサンハイセラ、CLLおよび濾胞性リンパ腫に対するガザイバ、再発性MSおよび原発性進行性MSに対するオクレバス、再発または難治性の濾胞性リンパ腫に対するルンスミオ、再発または難治性のびまん性大細胞型B細胞リンパ腫に対するグロフィタマブ、およびその他の抗CD20療法。バイオジェン社は、メルツ・セラピューティクス社、アルケルメス・ファーマ・アイルランド社、デナリ・セラピューティクス社、UCB社、エーザイ株式会社、ジェネンテック社、ニューリミューン・サブワン社、イオニス・ファーマシューティカルズ社、サムスン・バイオエピス社、セージ・セラピューティクス社と提携およびライセンス契約を結んでいる、また、Dravet症候群の治療薬であるzorevunersenの開発および商品化に関するStoke Therapeutics社、経口大環状ペプチドの開発に関するDayra Therapeutics社、Vanqua Bio, Inc ALT-B4を利用した生物製剤の皮下（SC）製剤を開発するALTEOGEN Inc.などである。同社は1978年に設立され、マサチューセッツ州ケンブリッジに本社を置いている。
Biogen Inc. 基礎のまとめ
| BIIB 基礎統計学 | |
|---|---|
| 時価総額 | US$27.92b |
| 収益（TTM） | US$1.37b |
| 売上高(TTM) | US$9.94b |
20.5x
PER（株価収益率2.8x
P/SレシオBIIB は割高か？
公正価値と評価分析を参照収益と収入
| BIIB 損益計算書（TTM） | |
|---|---|
| 収益 | US$9.94b |
| 売上原価 | US$2.11b |
| 売上総利益 | US$7.82b |
| その他の費用 | US$6.45b |
| 収益 | US$1.37b |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | 9.29 |
| グロス・マージン | 78.72% |
| 純利益率 | 13.81% |
| 有利子負債／自己資本比率 | 33.7% |
BIIB の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/05/06 20:22 |
| 終値 | 2026/05/06 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Biogen Inc. 22 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。58
| アナリスト | 機関 |
|---|---|
| David Toung | Argus Research Company |
| Brian Skorney | Baird |
| Emily Field | Barclays |